TARGOVAX ASA has a total of 56 patent applications. It decreased the IP activity by 40.0%. Its first patent ever was published in 2014. It filed its patents most often in EPO (European Patent Office), Chile and United States. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are UNIV HEIDELBERG RUPRECHT KARLS, BIONTECH RNA PHARMACEUTICALS GMBH and AUSPHARM INT LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 10 | |
#2 | Chile | 6 | |
#3 | United States | 6 | |
#4 | WIPO (World Intellectual Property Organization) | 5 | |
#5 | Australia | 4 | |
#6 | Singapore | 4 | |
#7 | Brazil | 3 | |
#8 | Canada | 3 | |
#9 | Israel | 3 | |
#10 | Republic of Korea | 3 | |
#11 | Mexico | 3 | |
#12 | Japan | 2 | |
#13 | China | 1 | |
#14 | Hungary | 1 | |
#15 | Serbia | 1 | |
#16 | Russian Federation | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Therapeutic chemical compounds | |
#4 | Microorganisms | |
#5 | Analysing materials | |
#6 | Measuring microorganism processes | |
#7 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Eriksen Jon Amund | 45 |
#2 | Gaudernack Gustav | 9 |
#3 | Jon Amund Eriksen | 8 |
#4 | Kuryk Lukasz | 6 |
#5 | Skorpil Peter | 6 |
#6 | Burns Robert | 6 |
#7 | Møller Anne-Sophie | 6 |
#8 | Gustav Gaudernack | 3 |
#9 | Jonsbu Einar | 1 |
#10 | Iversen Berit | 1 |
Publication | Filing date | Title |
---|---|---|
WO2020002650A1 | A formulation | |
EP3725888A1 | Oncolytic adenoviral vector expressing peptidylarginine deiminase and tissue inhibitor of metalloproteinase | |
EP3725322A1 | Oncolytic adenoviral vector expressing granzyme and perforin | |
EP3725323A1 | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada | |
KR20180021072A | Mutated fragment of RAS protein | |
RU2700929C2 | Peptide vaccine comprising ras peptide containing mutations, and chemotherapeutic agent | |
KR20160097290A | A peptide mixture |